288 Matching Annotations
  1. Nov 2022
    1. The way you deal with your time outside of work is a little bit different, and so I’m going to put that aside.

      I wonder in what ways the time outside of work is managed differently. In the end, it is all about allocating your time to the uses you decide on.

  2. Oct 2022
    1. Das Produktivitätsproblem muss inbezug auf eine Relation gestellt werden,nämlich in bezug auf die Relation vonZettelkasten und Benutzer.

      "The productivity problem must be formulated in the context of a relation, in the relation of the ZK and its user." This holds generally I suppose, productivity notions must be placed in the context of the producer and their tools. Where the producer also is the one formulating what counts as productivity. Vgl [[A Practice for Note Card Systems Outputs – Interdependent Thoughts 20221023140227]] Reading this I realise I have little purpose for e.g. economic measures of general population productivity, and e.g. in my company staying away from using billable hours as measure for productivity (but struggling to find another way to have such conversations, about effectiveness perhaps more than productivity)

  3. Aug 2022
    1. Chadeau-Hyam, M., Wang, H., Eales, O., Haw, D., Bodinier, B., Whitaker, M., Walters, C. E., Ainslie, K. E. C., Atchison, C., Fronterre, C., Diggle, P. J., Page, A. J., Trotter, A. J., Ashby, D., Barclay, W., Taylor, G., Cooke, G., Ward, H., Darzi, A., … Elliott, P. (2022). SARS-CoV-2 infection and vaccine effectiveness in England (REACT-1): A series of cross-sectional random community surveys. The Lancet Respiratory Medicine, 0(0). https://doi.org/10.1016/S2213-2600(21)00542-7

    1. Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leschinsky, M., Dror, S. K., Bergerzon, G., Gadban, H., Gadban, F., Eliassian, E., Shimron, O., Saleh, L., Ben-Zvi, H., Amichay, D., Ben-Dor, A., … Stern, A. (2021). Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2 mRNA vaccinated individuals. MedRxiv, 2021.04.06.21254882. https://doi.org/10.1101/2021.04.06.21254882

    1. Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., Shapiro, N. I., Gibbs, K. W., Files, D. C., Hager, D. N., Shehu, A., Prekker, M. E., Erickson, H. L., … Self, W. H. (2022). Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ, 376, e069761. https://doi.org/10.1136/bmj-2021-069761

  4. May 2022
  5. Apr 2022
    1. 🇺🇦 Meaghan Kall. (2022, January 27). NEW: 🏴󠁧󠁢󠁥󠁮󠁧󠁿 Vaccine effectiveness (symptomatic infection) data for BA.2 {Omicron’s more infectious sister} NO difference in VE between Omicron (BA.1) and BA.2 Possibly even higher VE for BA.2 but estimates overlap See full thread 🧵 from @freja_kirsebom https://t.co/bJ7uCn2cGV [Tweet]. @kallmemeg. https://twitter.com/kallmemeg/status/1486821549458001927

    1. Pérez-Then, E., Lucas, C., Monteiro, V. S., Miric, M., Brache, V., Cochon, L., Vogels, C. B. F., Cruz, E. D. la, Jorge, A., Santos, M. D. los, Leon, P., Breban, M. I., Billig, K., Yildirim, I., Pearson, C., Downing, R., Gagnon, E., Muyombwe, A., Razeq, J., … Iwasaki, A. (2021). Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience (p. 2021.12.27.21268459). medRxiv. https://doi.org/10.1101/2021.12.27.21268459

    1. 🇺🇦 Meaghan Kall [@kallmemeg]. (2021, December 23). VACCINES Speaking of boosters, it’s not great news I’m afraid. Updated vaccine effectiveness analysis shows mRNA boosters beginning to wane from one month (week 5-9) for Omicron, and as low as 30-50% effective from 10 weeks post-booster. This effect is not seen with Delta. Https://t.co/g0tLxH3vLR [Tweet]. Twitter. https://twitter.com/kallmemeg/status/1474072056878804992

    1. Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., AlMukdad, S., Tang, P., Hasan, M. R., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Bertollini, R. (2022). Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar (p. 2022.01.18.22269452). medRxiv. https://doi.org/10.1101/2022.01.18.22269452

  6. Mar 2022
    1. That’s all fine and well and good as long as you don’t have a crisis

      Systems that are too efficient will become brittle. Brittle systems collapse catastrophically when conditions vary too far from expectations. The only way to accommodate unforeseeable circumstances is to give up some efficiency for greater flexibility. This produces robust systems that endure where brittle systems collapse.

  7. Feb 2022
    1. ReconfigBehSci on Twitter: “RT @Gab_H_R: Effectiveness of mRNA-1273 against-Omicron and Delta variants ⚠️ The 3dose VE was 71.6% and 47.4% against Omicron infection (…” / Twitter. (n.d.). Retrieved February 22, 2022, from https://twitter.com/SciBeh/status/1496032262177136642

    1. Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., … Abu-Raddad, L. J. (2022). Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMc2200133

    1. Prof. Gavin Yamey MD MPH. (2022, January 21). His vax disinformation is at 34.55 in the video His full comments: “But people do not trust this vaccine. It’s not been through the normal trials, it’s a technology that’s not been proven as safe & effective, & now the data is coming in on the vaccine that’s showing that..” 1/3 [Tweet]. @GYamey. https://twitter.com/GYamey/status/1484668215825469445

  8. Jan 2022
    1. ReconfigBehSci. (2022, January 28). We’ve had at least 4 months of European governments tailoring policy to hospital capacity, not cases per se—So why are we still seeing arguments against the effectiveness of those policies based solely on cases, and not the actual target function? @AllysonPollock [Tweet]. @SciBeh. https://twitter.com/SciBeh/status/1487038050899222528

    1. Jennifer Cohn ✍🏻 📢. (2022, January 11). This chart says it all. If u got double vaccinated early on & are not yet boosted, ur effectively unvaccinated against Omicron infection. Thus, many adults & teens are effectively unvaccinated against infection. Kids got vaccinated recently & thus may be in a safer position. 1/ [Tweet]. @jennycohn1. https://twitter.com/jennycohn1/status/1481034404260581377

    1. Home

      Zuo, F., Abolhassani, H., Du, L., Piralla, A., Bertoglio, F., Campos-Mata, L. de, Wan, H., Schubert, M., Wang, Y., Sun, R., Cassaniti, I., Vlachiotis, S., Kumagai-Braesch, M., Andréll, J., Zhang, Z., Xue, Y., Wenzel, E. V., Calzolai, L., Varani, L., … Pan-Hammarström, Q. (2022). Heterologous immunization with inactivated vaccine followed by mRNA booster elicits strong humoral and cellular immune responses against the SARS-CoV-2 Omicron variant (p. 2022.01.04.22268755). https://doi.org/10.1101/2022.01.04.22268755

    1. Olson, S. M., Newhams, M. M., Halasa, N. B., Price, A. M., Boom, J. A., Sahni, L. C., Pannaraj, P. S., Irby, K., Walker, T. C., Schwartz, S. P., Maddux, A. B., Mack, E. H., Bradford, T. T., Schuster, J. E., Nofziger, R. A., Cameron, M. A., Chiotos, K., Cullimore, M. L., Gertz, S. J., … Randolph, A. G. (2022). Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2117995

    1. Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A., Kawabata, H., Sominsky, L., Clark, J., Adelsberg, D. C., Bielak, D., Gonzalez-Reiche, A. S., Dambrauskas, N., Vigdorovich, V., Group, P. S., Srivastava, K., Sather, D. N., Sordillo, E. M., Bajic, G., van Bakel, H., … Krammer, F. (2021). Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature. https://doi.org/10.1038/d41586-021-03846-z

  9. Dec 2021